References
Xu Z, Huang X. Cellular immunotherapy for hematological malignancy: recent progress and future perspectives. Cancer Biol Med. 2021; 18: 966-80.
Fornecker LM, Lazarovici J, Aurer I, Casasnovas RO, Gac AC, Bonnet C, et al. Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): a multicenter, open-label, randomized, phase Ⅱ trial. J Clin Oncol. 2023; 41: 327-35.
Herrera AF, LeBlanc M, Castellino SM, Li H, Rutherford SC, Evens AM, et al. Nivolumab(n)-Avd improves progression-free survival compared to brentuximab vedotin(BV)-Avd in advanced stage (AS) classic Hodgkin lymphoma (HL): results of SWOG S1826. Hematol Oncol. 2023; 41(S2): 33-5.
Vinti L, Daw S, Alvarez CS, Fagioli F, Beishuizen A, Michel G, et al. S215: KEYNOTE-667: open-label, phase 2 study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (CHL) with slow early response to front-line chemotherapy. HemaSphere. 2023; 7(S3): e3506076.
Borchmann P, Moccia AA, Greil R, Schneider G, Hertzberg M, Schaub V, et al. BRECADD is non-inferior to EBEACOPP in patients with advanced stage classical Hodgkin lymphoma: efficacy results of the GHSG phase Ⅲ HD21 trial. Hematol Oncol. 2023; 41(S2): 881-2.
Castellino SM, Pei Q, Parsons SK, Hodgson D, McCarten K, Horton T, et al. Brentuximab vedotin with chemotherapy in pediatric highrisk Hodgkin’s lymphoma. N Engl J Med. 2022; 387: 1649-60.
Herrera AF, Chen L, Nieto Y, Holmberg L, Johnston P, Mei M, et al. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial. Lancet Haematol. 2023; 10(1): e14-23.
Liu W, Lin N, Feng X, Xie Y, You C, Zhou X, et al. Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma. Signal Transduct Target Ther. 2023; 8: 356.
Harker-Murray P, Mauz-Körholz C, Leblanc T, Mascarin M, Michel G, Cooper S, et al. Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults. Blood. 2023; 141: 2075-84.
Zhang H, Yu J, Li H, Qian W, Xiao X, Cai Q, et al. S216: CD47/PD-L1 bispecific antibody (IBI322) in anti-PD-1 or PD-L1 treatment-resistant classical Hodgkin lymphoma: a phase Ⅰ study. HemaSphere. 2023; 7(S3): e8102841.
Ramos CA, Quach DH, Lulla PD, Rouce RH, Sharma S, Ganesh HR, et al. Off-the-shelf CD30.CAR-modified Epstein-Barr virusspecific T cells (CD30.CAR EBVSTS) provide a safe and effective therapy for patients with Hodgkin lymphoma (HL). Hematol Oncol. 2023; 41(S2): 83-5.
Dickinson MJ, Trotman J, Berkahn L, Butler J, Bressel M, Neeson P, et al. Pembrolizumab as first therapy for Hodgkin lymphoma is deliverable in older or ABVD-ineligible patients, allows subsequent therapy, and gives adequate survival. Hematol Oncol. 2023; 41(S2): 160-1.
Torka P, Feldman T, Savage K, Ganesan N, Hancock H, Davey T, et al. Phase 2 trial of nivolumab plus adriamycin, vinblastine, dacarbazine (N-AVD) as frontline therapy in older adults with Hodgkin lymphoma. Hematol Oncol. 2023; 41(S2): 161-2.
Lynch RC, Ujjani CS, Poh C, Warren EH, Smith SD, Shadman M, et al. Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma. Blood. 2023; 141: 2576-86.
Wang Y, Huang R, Wang Z, Xiong J, Wang X, Zhang X. Facing challenges with hope: universal immune cells for hematologic malignancies. Cancer Biol Med. 2023; 20: 229-47.
